Type 2 Diabetes Mellitus
Conditions
Brief summary
Primary Objective: To demonstrate safety of 14-day repeated lixisenatide doses with 3 ascending doses as compared to placebo in pediatric patients with T2DM. Secondary Objectives: * To evaluate plasma concentrations of lixisenatide after repeated doses (3 ascending doses) and pharmacokinetic parameters of repeated lixisenatide doses in pediatric patients with T2DM. * To evaluate the change from baseline in fasting and post-prandial plasma glucose concentrations during a standardized meal test after 3 ascending repeated doses of lixisenatide in comparison to placebo.
Detailed description
The total study duration will be up to 10 weeks that includes a 6-week treatment period with dose escalation every 2 weeks.
Interventions
DRUGLixisenatide (AVE0010)
Pharmaceutical form: solution Route of administration: subcutaneous
DRUGPlacebo
Pharmaceutical form: solution Route of administration: subcutaneous
DRUGBasal Insulin
Pharmaceutical form: solution Route of administration: subcutaneous
DRUGMetformin
Pharmaceutical form: tablet Route of administration: oral
Sponsors
Sanofi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Caregiver)
Eligibility
Sex/Gender
ALL
Age
10 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
: * Male or female patients aged ≥10 and \<18 years old (at least 4 patients below 16 years old). * Body mass index (BMI) \>85th percentile for age and gender; BMI ≤50 kg/m2. * Male and female patients with documented T2DM insufficiently controlled with metformin at a stable dose and regimen for 8 weeks prior to randomization and/or basal insulin at stable dose (± 20%) and regimen for 8 weeks prior to randomization. The exact individual metformin dose will be selected according to local regulation and to the investigator's medical judgment. * Glycated hemoglobin (HbA1c) \>6.5% and ≤11% at screening.
Exclusion criteria
* If female, ongoing pregnancy (defined as positive serum pregnancy test), breast-feeding. * Sexually active postmenarchal female patient who does not agree to use an adequate and highly effective method of contraception throughout the study duration and according to local regulation (ie, hormonal contraception, condom, etc.). * Diabetes other than T2DM. * Fasting plasma glucose \>250 mg/dL (\>13.9 mmol/L) at screening. * Use of other oral or injectable antidiabetic or hypoglycemic agents other than metformin and basal insulin (eg, alpha glucosidase inhibitor, glucagon-like peptide (GLP-1) receptor agonist, dipeptidyl peptidase-IV (DPP-IV) inhibitors, short-acting insulin etc.) within 1 month prior to the screening visit. * History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with adverse events (AEs) | Up to 10 weeks |
| Number of patients with treatment-emergent adverse events (TEAEs) | Up to 10 weeks |
| Number of patients with anti-lixisenatide antibodies | Up to 10 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of PK parameters: area under up to last concentration (AUClast) | Day 42 |
| Assessment of pharmacokinetic (PK) parameters: lixisenatide plasma concentration | Day 14, Day 28 and Day 42 |
| Assessment of pharmacodynamic parameter: plasma glucose AUC-0-4.5 hours | Day 14, Day 28 and Day 42 |
| Assessment of PK parameters: area under curve (AUC) | Day 42 |
| Assessment of PK parameters: maximum concentration (Cmax) | Day 42 |
| Assessment of PK parameters: time to reach Cmax (Tmax) | Day 42 |
Countries
Mauritius, Mexico, South Africa, Spain, Turkey (Türkiye), United States
Outcome results
None listed